Compare Howmet Aerospace Inc (HWM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Twist Bioscience Corp — how do they compare? Howmet Aerospace Inc trades at $282.01 (market cap $112.20B), while Twist Bioscience Corp trades at $124.64 (market cap $7.72B). The key difference: Howmet Aerospace Inc is far larger — about 14.5× Twist Bioscience Corp's market cap, and Howmet Aerospace Inc pays a 0.2% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| HWM | TWST | |
|---|---|---|
Market Cap | $112.20B | $7.72B |
Sector | Industrials | Health |
52-Week High | $291.28 | $124.88 |
52-Week Low | $171.00 | $24.16 |
Enterprise Value | $116.30B | $7.65B |
Dividend Yield | 0.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $281.63, down 0.73% on the day, with strong technical support at $279 and resistance at $285. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $1.33 exceeding expectations by 7.3%, driven by robust aerospace and defense demand. Analyst consensus remains strongly bullish with 84% buy ratings and a $334.63 price target, representing 19% upside potential.
Outlook remains positive with raised 2026 guidance and strong cash flow generation, though elevated valuation multiples (P/E 60.63) and significant capital expenditures present risks. The stock offers growth exposure to aerospace recovery but faces execution risks amid capacity expansion plans and supply chain challenges.
Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.
Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
